Caribou’s first CRISPR CAR-T impresses

Caribou’s first CRISPR CAR-T impresses

Caribou expects these PD-1 knockout allogeneic CAR T therapies may overcome durability concerns to deliver therapies that are as effective as autologous anti-CD19 CAR T therapies but at a fraction of the cost. Caribou was co-founded in 2011 by, among others, CRISPR pioneer and Nobel laureate Jennifer Doudna.

This is a preview of subscription content

Access options

Subscribe to Journal

Get full journal access for 1 year

99,00 €

only 8,25 € per issue

Tax calculation will be finalised during checkout.

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Cite this article

Caribou’s first CRISPR CAR-T impresses.
Nat Biotechnol 40, 807 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Read More

Author: admin